Seeks to amend notification No. 16/2017-Customs dated the 20th April, 2017 - 83/2017 - Customs -Tariff

GOVERNMENT OF INDIA MINISTRY OF FINANCE (DEPARTMENT OF REVENUE) Notification No. 83/2017-Customs New Delhi, the 31st October, 2017 G.S.R. 1356 (E). - In exercise of the powers conferred by sub-section (1) of section 25 of the Customs Act, 1962 (52 of 1962 ), the Central Government, on being satisfied that it is necessary in the public interest so to do, hereby makes the following further amendments in the notification of the Government of India, in the Ministry of Finance (Department of Revenue), No. 16/2017-Customs, dated the 20th April, 2017, published in the Gazette of India, Extraordinary, Part II, Section 3, Sub-section (i), vide number G.S.R.394 (E), dated the 20th April, 2017, namely: - In the said notification, in the Table, after serial number 27 and the entries relating thereto, the following serial numbers and entries shall be added, namely: - (1) (2) (3) (4) 28. Erlotinib (Tarceva) The Blue Tree Roche Products (India) Private Limited 29 Trastuzumab (Herclon) The Blue Tree Roche Products (India) Private Limited 30. Pertuzumab (Perjeta) The Blue Tree Roche Products (India) Private Limited 31. Transtuzumab Emtansine (Kadcyla) The Blue Tree Roche Products (India) Private Limited 32. Obinutuzumab (Gazyva) The Blue Tree Roche Products (India) Private Limited 33. Bevacizumab (Avastin) The Blue Tree Roche Products (India) Private Limited 34. Tocilizumab (Actemra) Care for Joints Roche Products (India) Private Limited 35. Mycophenolate Mofetil (CellCept) Aarambh Roche Products (India) Private Limited 36. Avonex (Interferon Beta 1A) Reach UCB India Private Limited 37. Tysabri (Monoclonal Antibody Reach UCB India Private Limited 38. Tecfidera (Di-methyl Fumarate) Reach UCB India Private Limited 39. Plegridy (Peggylated Interferon Beta 1A) Reach UCB India Private Limited 40. Sorafenib (Nexavar) NexCSP (Nexavar Cancer Survivorship Program) Bayer Zydus Pharma Private Limited 41. Sirturo (Bedaquiline) Bedaquiline Compassionate Use Program Janssen India, Johnson Johnson Private Limited 42. Darzalex (Daratumumab) Daratumumab Patient Assistance Program Janssen India, Johnson Johnson Private Limited 43. SUTENT - Patients initially pay for 12 strips (value equivalent of 50 mg) and gets assistance of 12 strips free. - Post purchase of 12 strips patients receive the drug free until prescribed by treating physicians. -Full subsidy for BPL patients Pfizer Products India Private Limited 44. CRIZALK Patients will pay for 8 bottles (either 200 mg or 250 mg) and post that will get the drug free until prescribed by treating physician. - Full subsidy for BPL patients Pfizer Products India Private Limited 45. INLYTA Sutent Patients who progresses and prescribed lnlyta as 2nd line pays for 1 strip and gets 1 strip free. - Patients who progresses on other 1st line TKI pays for 2 strips and get 1 strip free. -Ful1subsidy for BPL patients Pfizer Products India Private Limited 46. PALBACE -Patients will pay for 10 cycles and post that will get free drug support until prescribed by treating physicians. - Full subsidy for BPL patients Pfizer Products India Private Limited 47. ENBREL ENLIVEN -Enbrel 50 mg: 4+2PAP. Any further repeat purchase will be given at a further discounted price -Enbrel25mg: 8+4 PAP. Any further repeat purchase will be given at a further discounted price Pfizer Limited 48. XELJANZ XELSOURCE India specific price of ₹ 24000 per bottle (MRP is ₹ 66000 per bottle) Pfizer Limited 49. GENPTROPIN 5+1 PAP Pfizer Products India Private Limited 50. Atgam For AIIMS Delhi 5+1, KEM Mumbai 4+1, CMC Vellore 4+1 Other hospitals 20+4 Pfizer Products India Private Limited 51. Aromasin PAP 1+1 Pfizer Products India Private Limited 52. Campto PAP 1+1 Pfizer Products India Private Limited . [F. No. 332/24/2010-TRU (Pt. I)] (Ruchi Bisht) Under Secretary to the Government of India Note: The principal notification No. 16/2017-Customs, dated the 20th April, 2017, published in the Gazette of India, Extraordinary, Part II, Section 3, Sub-section (i) vide number G.S.R.394 (E), dated the 20th April, 2017.